Why the study?
Older patients with AF face high risks of stroke, bleeding, and death, yet have been underrepresented in randomized clinical trials.
This review highlights that despite underrepresentation in clinical trials, elderly patients with atrial fibrillation can benefit from modern therapies like DOACs and individualized rhythm control strategies.
Elderly AF patients remain underrepresented in RCTs; leaves open optimal management strategies for this high-risk group.
In older age, patients with atrial fibrillation (AF) have a high risk of stroke, bleeding, and death, but such patients have been underrepresented in randomized clinical trials. A search and analysis of 4 176 literature sources from the MEDLINE/ PubMed and eLIBRARY databases was carried out for the keywords «atrial fibrillation», «old age», «older», «elderly». The review includes the most important studies reflecting the current understanding of risk factors for development, complications and treatment of AF in old age. The results of therapy to control the ventricular rate, to control sinus rhythm in AF with drugs and catheter ablation are discussed. The data of studies on the prevention of thromboembolic complications in patients with AF by the use of anticoagulants and implantable devices are considered.
No takes yet. Share an insight, caveat, or question.
С. Г. Канорский (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: